Neuromuscular Program
Late-onset Pompe disease
PreclinicalActive
Key Facts
About Creyon Bio
Creyon Bio is a private, pre-clinical biotech company pioneering a novel approach to RNA drug delivery using aptamers and artificial intelligence. Its core technology platform aims to overcome key limitations of traditional antibody-based delivery and lipid nanoparticles by enabling precise, cell-specific targeting of therapeutic payloads like siRNA and ASOs. The company has established preclinical proof-of-concept in three therapeutic areas—immunology, CNS, and neuromuscular diseases—and is advancing a wholly-owned pipeline. Creyon represents a convergence of next-generation delivery science and computational drug design, positioning it to develop potentially safer and more effective RNA therapies.
View full company profileTherapeutic Areas
Other Late-onset Pompe disease Drugs
| Drug | Company | Phase |
|---|---|---|
| AT845 (FORCE) | astellas | Phase 1/2 |
| AT845 | Astellas Pharma | Phase 1/2 |